PDCD1 and neoplasm: For example, peripheral metastases from renal cell carcinoma are almost two times more sensitive to anti-PD-1 therapy than brain metastases of the same tumor [139], and in a murine glioma model, orthotopic tumors are far more refractory to ICI than subcutaneous tumors [140].